| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood. However, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. In the present study, we investigated whether the targeted inhibition of PDGF signal by using a complementary peptide, has the potential to regulate pulmonary fibrosis. Complementary peptides inhibited the proliferation of lung fibroblasts in response to PDGF. Additionally, we showed that complementary peptides bind to the surface of lung fibroblasts using immunofluorescence staining. Transbronchial administration of complementary peptides ameliorated the pulmonary fibrosis induced by bleomycin in mice. These data suggest that it can become a promising target for therapeutic approaches to pulmonary fibrosis.
|
